- Gilead Sciences faces a $61 million impact on Q2 earnings due to research and development charges.
- Analysts forecast an average price target of $116.87, implying a 6.60% upside.
- Gilead carries an "Outperform" rating with a brokerage recommendation of 2.0.
Gilead Sciences Inc. (NASDAQ: GILD) has disclosed that its second-quarter earnings will be significantly impacted by $61 million in acquired in-process research and development charges. Notably, this financial burden is projected to decrease both GAAP and non-GAAP EPS by around $0.04. The company highlighted that $40 million of these charges are attributed to its recent partnership with Kymera Therapeutics, a strategic move aimed at advancing cancer drug development.
Wall Street Analysts' Forecast
Examining the insights of 24 prominent analysts, Gilead Sciences Inc. (GILD, Financial) maintains an average one-year price target of $116.87. Projections span from a high of $140.00 to a low of $93.00, suggesting a potential upside of 6.60% from its current trading price of $109.64. To explore more comprehensive estimate data, visit the Gilead Sciences Forecast page.
With input from 30 brokerage firms, the consensus recommendation for Gilead Sciences is "Outperform," marked at an average recommendation of 2.0 on a scale where 1 denotes a Strong Buy and 5 signifies a Sell.
According to GuruFocus estimates, the projected GF Value for Gilead Sciences in one year is calculated at $84.27. This projection indicates a possible downside of 23.14% against the current market price of $109.64. The GF Value represents GuruFocus’ estimation of the stock's fair trading value, derived from historical trading multiples, past business growth, and future performance forecasts. For more in-depth insights, visit the Gilead Sciences Summary page.
